Metrics matter: Toward consensus reporting of BMI and weight‐related outcomes in pediatric obesity clinical trials

Abstract

JRR receives support from Boehringer Ingelheim Pharmaceuticals in the form of drug/placebo. JRR serves as a consultant for Novo Nordisk A/S and Eli Lilly and Company; he does not accept personal or professional income for his services. ASK serves as a consultant for Novo Nordisk A/S, Vivus, and Eli Lilly and Company; he does not accept personal or professional income for his services. ASK also receives research support from Vivus in the form of drug/placebo. The other authors declared no conflict of interest. This report’s findings and conclusions are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Topics & Concepts